Deliver Consulting Limited | Back to main site
Home > Forum Agenda > Program Overview

Program Overview

As one of the effective means of precision medicine, Nucleic Acid-based Medicines can directly act on the target genes or target mRNA and regulate the expression of the therapeutic genes from the root. The RNA-based medicines have greatly expanded the range of selectable targets of innovative drugs, making the previously undruggable targets possible. In recent years, with the maturation of technologies for chemical modification, nucleic acids delivery and manufacturing, the RNA-based Therapeutics is expanding rapidly with multiple products launch onto the market, showing increasingly prominent clinical advantage and market value.

With the successful development of COVID19 mRNA vaccine recently, this new class of medicine gradually enter the public vision and has also shown great potential in the field of infectious diseases, oncology treatment and orphan drug area. In Return, xRNA Therapeutics Development and Innovation Forum 2023 will gather leaders and scientists across RNA-based medicines Innovators, leading academic centers and institutes for the discussion and case studies with the aim to facilitate the communication and partnership for the development, delivery and manufacturing of the next generation nucleic-acid-based vaccines and therapeutics

Session I: mRNA and circRNA Vaccines and Therapeutics  

  • Prospects in the Development and Application of Next Generation mRNA-based Therapeutics 
  • Challenges and Strategies for the mRNA Vaccine Industrialization
  • Development of mRNA Vaccines for COVID19 and other Infectious Diseases
  • Progress on the Development of mRNA Cancer Vaccines
  • Advances in the Development of Cellular Therapy based on mRNA editing
  • Non-Clinical Safety Evaluation and Clinical Development Strategies for mRNA Vaccines
  • The Applications of circRNA in Therapeutic Development and CMC Strategies and more

Session II: CMC, Analytical and Process Development for mRNA Vaccines and Therapeutics

  • Challenges in the Analysis of mRNA Vaccine and Therapeutics
  • Progress of USP Quality Analysis Standard for mRNA Vaccine
  • Analytical Method Development, Quality Control Strategies for mRNA Vaccines
  • Process Development and Optimization Strategies for mRNA Vaccines
  • mRNA Vaccine upstream process development and purification development and more

Session III: Small Nucleic Acid Drugs (ASO, siRNA, saRNA etc.) and CMC Strategies

  • Challenges and Strategy for the Development of Nucleic Acid Drugs
  • The Current Market Landscape and Future Development Analysis of RNA-based Medicines in China 
  • The Frontiers and Delivery Challenges of siRNA Therapeutics and ASO
  • Development small activating RNA (saRNA) as the Therapeutic: Challenges and Opportunities
  • Process Development and Optimization Strategies for Oligonucleotides Therapeutics
  • The Application of LC-MS Technology for the Analysis and Quantitation of Oligonucleotides and more

Session IV: Delivery Strategies and Technology for RNA-based Therapeutics

  • Mechanism for mRNA-LNP vaccine in vivo delivery and Pharmacokinetics studies
  • Progress on the Development of Novel Nucleic Acid Drugs based on Cell Like System Delivery Technology 
  • Development of LNPs for Safe and Effective mRNA Delivery
  • LNP nucleic acid drug delivery system based on novel cationic lipid material
  • Self-assembled In Vivo Delivery System for RNA-based Therapeutics 
  • Polypeptide-based nucleic acid drug delivery system and more

Currently we are receiving the podium/poster abstracts. If you are working in the above areas, you are invited to submit a proposal. For more information, please contact 

Wei Zhang
Program Manager
Organizing Committee
Phone: (86) 21-2250-2516